Ladenburg Thalmann Financial Services Initiates Coverage on Alnylam Pharmaceuticals, Inc.

Ladenburg Thalmann Financial Services Initiates Coverage on Alnylam Pharmaceuticals, Inc.


The brokerage set a "buy" rating and a $75.00 price target on the biopharmaceutical company's stock. Ladenburg Thalmann Financial Services' target price points to a potential upside of 80.90% from the stock's current price.



from Biotech News